Pharmacokinetics and bioequivalence study of esomeprazole magnesium enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions

Ying Ding, Nannan Chu, Linling Que, Kai Huang, Yuanxing Chen, Qin Wei, Zhenzhong Qian, Yunfei Shi, Zhen Xu, Qing HeFrontiers in Pharmacology 2023 · DOI

Abstract

Objective: This study evaluated the pharmacokinetics, bioequivalence, and safety of a new generic vs. brand reference esomeprazole enteric-coated tablet (20 mg) in healthy Chinese subjects under fasting and fed conditions. Methods: A fasting study (n=32, two-period crossover) and a fed study (n=40, four-period crossover) were conducted. Plasma concentrations were measured via HPLC-MS/MS. Bioequivalence was assessed using 90% confidence intervals (CIs) for geometric mean ratios (GMRs) of $C_{max}$ and $AUC$. Results: Pharmacokinetics were similar between formulations. Under fasting, 90% CIs for $C_{max}$ and $AUC_{0-t}$ were 87.92%-104.36% and 87.82%-101.45%. Under fed conditions, they were 80.53%-94.95% and 87.46%-97.26%. All results fell within the regulatory bioequivalence range of 80.00%-125.00%. Both formulations were well-tolerated. Conclusion: The generic and reference products are bioequivalent and safe in healthy Chinese subjects.

Introduction

Gastroesophageal reflux disease (GERD) is a global health issue with rising incidence. Proton pump inhibitors (PPIs) like esomeprazole are the gold standard for treatment, but brand-name versions can be an economic burden on healthcare systems. While esomeprazole is well-studied, there was a specific data gap: a lack of pharmacokinetic (PK) and bioequivalence data for the 20 mg enteric-coated dosage specifically within the Chinese population. Factors like body weight, diet, and genetic polymorphisms (specifically the CYP2C19 enzyme) can alter drug metabolism, necessitating local "fasting and fed" studies to ensure generic performance matches the original before market entry.

Methods

The researchers conducted two separate, open-label, randomized crossover studies at Wuxi People’s Hospital:

  1. Fasting Study (n=32): A standard two-period crossover design where subjects received either the test or reference drug, followed by a 7-day washout period.
  2. Fed Study (n=40): A four-period crossover design (TRTR or RTRT). This design was chosen because food intake often increases the variability of drug absorption, requiring more data points to achieve statistical power. Subjects consumed a high-fat, high-calorie breakfast before dosing.
Study design and disposition of subjects.

Plasma concentrations were measured using High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS). The team calculated $C_{max}$ (peak concentration), $T_{max}$ (time to peak), and $AUC$ (total drug exposure). Bioequivalence was established if the 90% Confidence Intervals (CIs) for the ratio of the generic to the brand-name drug fell within the strict regulatory window of 80.00% to 125.00%.

Results and Discussion

Bioequivalence and Safety

The generic formulation met all regulatory requirements. In the fasting study, 90% CIs for $C_{max}$ and $AUC_{0-t}$ were 87.92%–104.36% and 87.82%–101.45%, respectively. In the fed study, they were 80.53%–94.95% for $C_{max}$ and 87.46%–97.26% for $AUC_{0-t}$. Both formulations were well-tolerated, with only mild, transient adverse events reported, such as temporary decreases in white blood cell counts.

The "Food Effect" and Population Specifics

The study confirmed that food significantly hinders esomeprazole absorption. In the fed state, $C_{max}$ and $AUC$ dropped by approximately 40%, and $T_{max}$ was delayed from 2 to 3.5 hours. This reinforces the clinical recommendation to take PPIs on an empty stomach. Interestingly, Chinese subjects showed lower $C_{max}$ but higher $AUC$ compared to previous data from Caucasian subjects, likely due to lower average body weight or a higher prevalence of CYP2C19 "poor metabolizer" genotypes in Asian populations.

Conclusion

The generic 20 mg esomeprazole enteric-coated tablet is bioequivalent to the reference product in healthy Chinese subjects under both fasting and fed conditions. While the study did not include CYP2C19 genotyping, it confirms the generic's safety and performance, offering a more affordable treatment option for acid-related disorders in China.

Summary updated

Abstract

<b>Objective:</b> The main purpose of this study was to evaluate the pharmacokinetics, bioequivalence, and safety properties between a new generic and a brand reference formulation of esomeprazole enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions. <b>Methods:</b> The fasting study was an open-label, randomized, two-period crossover study conducted in 32 healthy Chinese volunteers, and the fed study was a four-period crossover study conducted in 40 healthy Chinese volunteers. Blood samples were collected at the specified time points and determined to obtain the plasma concentrations of esomeprazole. The primary pharmacokinetic parameters were calculated using the non-compartment method. Bioequivalence was analyzed by the geometric mean ratios (GMRs) of the two formulations and the corresponding 90% confidence intervals (CIs). The safety of the two formulations was assessed. <b>Results:</b> The fasting and fed study showed that the pharmacokinetics of the two formulations was similar. Under the fasting condition, the 90% CIs of GMRs of the test-to-reference formulation were 87.92%-104.36% for C<sub>max</sub>, 87.82%-101.45% for AUC<sub>0-t</sub>, and 87.99%-101.54% for AUC<sub>0-∞</sub>; under the fed condition, the 90% CIs of GMRs of the test-to-reference formulation were 80.53%-94.95% for C<sub>max</sub>, 87.46%-97.26% for AUC<sub>0-t</sub>, and 87.46%-97.16% for AUC<sub>0-∞</sub>. The 90% CIs of GMRs fall within the bioequivalence range of 80.00%-125.00%. The two formulations had good safety and were well-tolerated, and no serious adverse events occurred. <b>Conclusion:</b> According to relevant regulatory standards, esomeprazole enteric-coated generic and reference products exhibited bioequivalence and good safety in healthy Chinese subjects. <b>Clinical Trials Registration:</b> http://www.chinadrugtrials.org.cn/index.html, identifier CTR20171347 and CTR20171484.
BibTeX
@inproceedings{ding2023pharmacokinetics,
  author = {Ying Ding and Nannan Chu and Linling Que and Kai Huang and Yuanxing Chen and Qin Wei and Zhenzhong Qian and Yunfei Shi and Zhen Xu and Qing He},
  title = {{Pharmacokinetics and bioequivalence study of esomeprazole magnesium enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1169103},
}
Figure